Talia Mota
Overview
Explore the profile of Talia Mota including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
166
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mutascio S, Mota T, Franchitti L, Sharma A, Willemse A, Bergstresser S, et al.
Immunity
. 2023 Apr;
56(5):1132-1147.e6.
PMID: 37030290
HIV infection persists during antiretroviral therapy (ART) due to a reservoir of latently infected cells that harbor replication-competent virus and evade immunity. Previous ex vivo studies suggested that CD8 T ...
2.
Pinzone M, VanBelzen D, Weissman S, Bertuccio M, Cannon L, Venanzi-Rullo E, et al.
Nat Commun
. 2019 Feb;
10(1):728.
PMID: 30760706
After initiating antiretroviral therapy (ART), a rapid decline in HIV viral load is followed by a long period of undetectable viremia. Viral outgrowth assay suggests the reservoir continues to decline...
3.
Flerin N, Bardhi A, Zheng J, Korom M, Folkvord J, Kovacs C, et al.
J Virol
. 2019 Jan;
93(6).
PMID: 30626677
Curing HIV infection has been thwarted by the persistent reservoir of latently infected CD4 T cells, which reinitiate systemic infection after antiretroviral therapy (ART) interruption. To evaluate reservoir depletion strategies,...
4.
Kumar N, van der Sluis R, Mota T, Pascoe R, Evans V, Lewin S, et al.
J Immunol
. 2018 Jul;
201(5):1468-1477.
PMID: 30030324
HIV latency occurs predominantly in long-lived resting CD4 T cells; however, latent infection also occurs in T cell subsets, including proliferating CD4 T cells. We compared the establishment and maintenance...
5.
Murray J, Maher S, Mota T, Suzuki K, Kelleher A, Center R, et al.
PLoS One
. 2017 Feb;
12(2):e0171572.
PMID: 28187204
Significant progress has been made in characterizing broadly neutralizing antibodies against the HIV envelope glycoprotein Env, but an effective vaccine has proven elusive. Vaccine development would be facilitated if common...